Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted ...

Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment ...

Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and ...

The San Diego start-up has three candidates targeting PARP1, one of a family of enzymes that is already a validated target in ovarian, breast, prostate and pancreatic cancers with approved ...

AZ has been presenting preclinical data from AZD5305, its next-generation PARP1 inhibitor at the 2021 American Association for Cancer Research meeting, which the company thinks could be more ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

Department of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria Christian Doppler Laboratory ...

Breast cancer is caused by the development of malignant cells in the breast. The malignant cells originate in the lining of the milk glands or ducts of the breast (ductal epithelium). Breast ...